EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency

Yuka Oi-Yo iD, Shin Urai iD, Masaaki Yamamoto iD, Seiji Tomofuji, Yuka Ohmachi iD, Yuriko Sasaki, Hironori Bando iD, Michiko Takahashi, Genzo Iguchi iD, Risa Harada, Yoshitada Sakai iD, Hidenori Fukuoka iD

The Journal of Clinical Endocrinology & Metabolism · 13.08.2026 · 111 (9) · e2096-e2107

DOI: 10.1210/clinem/dgag153 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 07.04.2026. Verfasst von Yuka Oi-Yo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. Hauptthemen laut MEDLINE: Human Growth Hormone, Muscle Strength, Dwarfism, Pituitary. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Foundation for Growth Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Once-weekly somapacitan is approved for treating adults with growth hormone deficiency. Phase 3 trials support its noninferiority to daily growth hormone (GH); however, its effect on comprehensive metabolic outcome, including muscle strength, during routine care, remains unclear.

Objective

To compare the metabolic and functional outcomes in patients who switched from daily GH to somapacitan with those who continued daily GH.

Methods

Prospective, observational, nonrandomized comparative study conducted from baseline to 52 weeks. This study was conducted at a single-center providing routine endocrine management. Fifty-seven adults on growth hormone replacement therapy were self-selected to receive either once-weekly or continued daily GH. Switching from daily GH to once-weekly somapacitan, or continuing daily treatment based on patient preference. The prespecified primary endpoint was the dual-energy X-ray absorptiometry-derived change in total lean mass from baseline to week 52. Exploratory endpoints included body composition, lipid profile, and physical performance.

Results

Baseline and week 52 insulin-like growth factor 1 standard deviation scores distributions were similar between the groups; yet the increase was greater with daily GH than with somapacitan. The primary endpoint showed no between-group difference (mean difference −0.2 kg; 95% CI −1.5 to 1.1). Somapacitan was associated with increased adiposity indices, yet it improved high-density lipoprotein-cholesterol. Exploratory analyses revealed improvements in handgrip strength and Timed Up and Go Test. No new safety concerns were observed.

Conclusion

In routine practice, switching to once-weekly somapacitan was associated with improved functional outcomes, despite less favorable adiposity trajectories, compared with daily therapy. Further studies are required to clarify long-term effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneMuscle StrengthDwarfism, PituitaryHumansFemaleAdultMaleBody CompositionProspective StudiesMiddle AgedHormone Replacement TherapyDrug SubstitutionTreatment OutcomeAbsorptiometry, PhotonDrug Administration Schedule

Stichwörter der Autor:innen

adults with growth hormone deficiencymetabolic outcomesonce-weekly growth hormonephysical performancesomapacitansomatropin

Substanzen

Human Growth Hormone

Autor:innen und Institutionen

  • Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
  • Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Hospital, Kobe 650-0017, Japan.
  • Department of Nutrition, Kobe University Hospital, Kobe 650-0017, Japan.
  • Faculty of Clinical Nutrition and Dietetics, Department of Clinical Nutrition and Dietetics, Konan Women's University, Kobe 658-0001, Japan.
  • Division of Rehabilitation Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

ORCID-Profile: Yuka Oi-Yo, Shin Urai, Masaaki Yamamoto, Yuka Ohmachi, Hironori Bando, Genzo Iguchi, Yoshitada Sakai, Hidenori Fukuoka

Förderung

  • Japan Society for the Promotion of Science
  • Foundation for Growth Science

Zitieren

APA

Oi-Yo, Y., Urai, S., Yamamoto, M., Tomofuji, S., Ohmachi, Y., Sasaki, Y., Bando, H., Takahashi, M., Iguchi, G., Harada, R., Sakai, Y., & Fukuoka, H. (2026). Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency. The Journal of Clinical Endocrinology & Metabolism, 111(9), e2096-e2107. https://doi.org/10.1210/clinem/dgag153

Vancouver

Oi-Yo Y, Urai S, Yamamoto M, Tomofuji S, Ohmachi Y, Sasaki Y, et al. Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency. The Journal of Clinical Endocrinology & Metabolism. 2026;111(9):e2096-e2107. doi:10.1210/clinem/dgag153

BibTeX
@article{OiYo2026,
  author = {Oi-Yo, Yuka and Urai, Shin and Yamamoto, Masaaki and Tomofuji, Seiji and Ohmachi, Yuka and Sasaki, Yuriko and Bando, Hironori and Takahashi, Michiko and Iguchi, Genzo and Harada, Risa and Sakai, Yoshitada and Fukuoka, Hidenori},
  title = {Metabolic and muscular effects of switching from somatropin to somapacitan in adults with growth hormone deficiency},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {9},
  pages = {e2096--e2107},
  doi = {10.1210/clinem/dgag153}
}
Kostenlos starten →